A recent study indicates that individuals who discontinue popular GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who stop traditional lifestyle plans.
Research printed in a prominent health publication shows that while overweight people often shed a large proportion of their body weight while undergoing treatment, the mass returns at an average rate of nearly a kilo each month once they quit.
"People using these drugs should be aware of the risk of quick weight regain when the treatment concludes," warns expert Dr. Susan Jebb.
This pace of regain suggests a reversion to original mass in about one and a half years.
Analyzing Therapies
The study, which reviewed dozens of trials involving over 9,000 of participants, compared the effects of these new drugs with older methods.
Scientists point out that individuals who lose weight through lifestyle changes alone generally experience a less rapid weight regain—approximately 100 grams monthly—once they finish.
Understanding the Fast Regain
Doctors suggest the mechanism of the drugs is key to understanding the amplified rebound.
These medications mimic a natural hormone called GLP-1, which controls hunger.
"Long-term administration of GLP-1 levels far above than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this medication means hunger is uncontrolled, making binge eating much more probable."
A Lifelong Issue?
The NHS suggest the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Professionals argue that, given the likelihood of relapse, the treatment is often ongoing.
This view is echoed by pharmaceutical companies, who state that the results "underscore the persistent character of obesity," similar to managing conditions like hypertension.
User Experiences
People who have come off the medication describe a intense resurgence of hunger.
"I experienced a trigger that goes on and I was suddenly extremely hungry," said a patient.
The struggle is compounded if patients have not developed permanent lifestyle or habit changes during therapy.
Widespread Use
Recent estimates suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is greater among females than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Finally, researchers emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a magic cure and lasting health benefits relies on integrated lifestyle management.